Poland· PL-100525890
Ogsiveo
A other antineoplastic agents product containing nirogacestatum, registered in Poland by SpringWorks Therapeutics Ireland Limited. The same ATC class is registered in 5 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Nirogacestatum is registered in 5 of 19 countries.
Countries holding a registration under ATC L01XX (other antineoplastic agents), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 3 of them publish a price we can compare per daily dose
Nirogacestatum · ATC L01XX
5 / 19 countries
- Denmark
- Finlandprice
- Ireland
- Polandprice
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Nirogacestatum
- Manufacturer
- SpringWorks Therapeutics Ireland Limited
- Country
- Poland (PL)
- ATC code
- L01XX
- ATC class
- Other antineoplastic agents
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Nirogacestatum in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaOGSIVEOMerck Europe B.V., Amsterdam
- BelgiumOgsiveo 50 mgMerck Europe
- FinlandOgsiveoMerck Europe B.V.
- IrelandOgsiveo 50 mg film‑coated tabletsMerck Europe B.V.
- IcelandOgsiveoMerck Europe B.V.*
- SwedenOgsiveo 50 mg Filmdragerad tablettMerck Europe B.V.
- United StatesOGSIVEOSpringWorks Therapeutics, Inc.
- SpainOGSIVEO 100 MG COMPRIMIDOS RECUBIERTOS CON PELICULAMerck Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Ogsiveo
- Liechtenstein · Ogsiveo
- Norway · Ogsiveo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/730bb739-7255-433e-82dc-03eac1cef15f GET /v1/drugs/730bb739-7255-433e-82dc-03eac1cef15f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "50 mg",
"packaging": "Rp ¦ EU/1/25/1932/001 ¦ 163961\n120 tabl.\nRp ¦ EU/1/25/1932/002 ¦ 163962\n180 tabl.",
"substance": "Nirogacestatum 50 mg",
"common_name": "Nirogacestatum",
"pl_product_id": "100525890",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about nirogacestatum.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.